Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2–CCR2 signaling

[1]  Y. Shin,et al.  Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer , 2021, Frontiers in Oncology.

[2]  M. Kwon Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer , 2019, Archives of Pharmacal Research.

[3]  M. Hung,et al.  Mechanisms Controlling PD-L1 Expression in Cancer. , 2019, Molecular cell.

[4]  Z. Fernández-Muñiz,et al.  MMP11 expression in intratumoral inflammatory cells in breast cancer , 2019, Histopathology.

[5]  Xiaobing Chen,et al.  CCL2 promotes cell migration by inducing epithelial-mesenchymal transition in oral squamous cell carcinoma. , 2019, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[6]  G. Murray,et al.  Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis , 2019, The Journal of pathology.

[7]  J. Jonkers,et al.  Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment , 2018, Cancer and Metastasis Reviews.

[8]  E. D. de Vries,et al.  Tumor-associated macrophages in breast cancer: Innocent bystander or important player? , 2018, Cancer treatment reviews.

[9]  Eun-sook Kim,et al.  Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9. , 2018, Cancer letters.

[10]  J. Pollard,et al.  A Unidirectional Transition from Migratory to Perivascular Macrophage Is Required for Tumor Cell Intravasation , 2018, Cell reports.

[11]  Jennifer L. Guerriero Macrophages: The Road Less Traveled, Changing Anticancer Therapy. , 2018, Trends in molecular medicine.

[12]  A. Andicoechea,et al.  Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes , 2017, Clinical breast cancer.

[13]  D. Radisky,et al.  Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer , 2017, Journal of cellular biochemistry.

[14]  Jeong Eon Lee,et al.  MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer , 2017, Breast Cancer Research and Treatment.

[15]  Shun-Fa Yang,et al.  MMP-11 promoted the oral cancer migration and FAK/Src activation , 2017, Oncotarget.

[16]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[17]  B. Rollins,et al.  CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice , 2016, PloS one.

[18]  J. Ahn,et al.  Gene Expression Profiling of Breast Cancer Brain Metastasis , 2016, Scientific Reports.

[19]  M. Yao,et al.  Elevated expression of chemokine C-C ligand 2 in stroma is associated with recurrent basal-like breast cancers , 2016, Modern Pathology.

[20]  R. Muschel,et al.  Targeting the CCL2-CCR2 signaling axis in cancer metastasis , 2016, Oncotarget.

[21]  S. Yeh,et al.  Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals , 2015, Oncotarget.

[22]  Yanping Zhang,et al.  Gene expression profiling leads to discovery of correlation of matrix metalloproteinase 11 and heparanase 2 in breast cancer progression , 2015, BMC Cancer.

[23]  Kunwei Shen,et al.  Stromal cells in tumor microenvironment and breast cancer , 2012, Cancer and Metastasis Reviews.

[24]  Chih-Hsin Tang,et al.  CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-κB signaling pathway. , 2012, Biochemical pharmacology.

[25]  Hongjoo Kim,et al.  Diagnostic and Prognostic Relevance of MMP-11 Expression in the Stromal Fibroblast-Like Cells Adjacent to Invasive Ductal Carcinoma of the Breast , 2012, Annals of Surgical Oncology.

[26]  M. Furihata,et al.  Matrix metalloproteinase-11 overexpressed in lobular carcinoma cells of the breast promotes anoikis resistance , 2011, Virchows Archiv.

[27]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[28]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[29]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[30]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[31]  J. Lee,et al.  Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival , 2010, BMC Cancer.

[32]  M. Moses,et al.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Xiao-Jun Ma,et al.  Gene expression profiling of the tumor microenvironment during breast cancer progression , 2009, Breast Cancer Research.

[34]  A. Ben-Baruch,et al.  The inflammatory chemokines CCL2 and CCL5 in breast cancer. , 2008, Cancer letters.

[35]  L. Matrisian,et al.  The other side of MMPs: Protective roles in tumor progression , 2007, Cancer and Metastasis Reviews.

[36]  D. Mennerich,et al.  Stromelysin-3 over-expression enhances tumourigenesis in MCF-7 and MDA-MB-231 breast cancer cell lines: involvement of the IGF-1 signalling pathway , 2007, BMC Cancer.

[37]  G. Collins The next generation. , 2006, Scientific American.

[38]  Wenmei Li,et al.  Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. , 2005, Biochemical and biophysical research communications.

[39]  L. Haupt,et al.  Stimulation of MMP-11 (stromelysin-3) expression in mouse fibroblasts by cytokines, collagen and co-culture with human breast cancer cell lines , 2004, BMC Cancer.

[40]  L. Hefler,et al.  Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer , 2004, Tumor Biology.

[41]  Carole Mathelin,et al.  Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. , 2003, Cancer research.

[42]  M. Shipp,et al.  Active stromelysin‐3 (MMP‐11) increases MCF‐7 survival in three‐dimensional Matrigel culture via activation of p42/p44 MAP‐kinase , 2003, International journal of cancer.

[43]  C. Sautès-Fridman,et al.  High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. , 2001, Cancer research.

[44]  H. Saji,et al.  Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  M. Barbacid,et al.  Identification of Insulin-like Growth Factor-binding Protein-1 as a Potential Physiological Substrate for Human Stromelysin-3* , 1997, The Journal of Biological Chemistry.

[46]  Stephen J. Weiss,et al.  Furin-dependent intracellular activation of the human stromelysin-3 zymogen , 1995, Nature.

[47]  S. Weiss,et al.  Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. , 1994, The Journal of biological chemistry.

[48]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.